Jane Street Group LLC acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,316 shares of the company's stock, valued at approximately $556,000. Jane Street Group LLC owned about 0.07% of Dianthus Therapeutics as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of DNTH. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after acquiring an additional 1,124 shares during the period. Fred Alger Management LLC grew its stake in shares of Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock worth $264,000 after purchasing an additional 3,316 shares during the last quarter. SG Americas Securities LLC increased its holdings in Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock valued at $242,000 after purchasing an additional 4,506 shares during the period. MetLife Investment Management LLC raised its position in Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company's stock worth $382,000 after purchasing an additional 7,854 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after purchasing an additional 8,473 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.
Dianthus Therapeutics Stock Up 7.6 %
DNTH traded up $1.92 during midday trading on Monday, hitting $27.04. The company had a trading volume of 484,832 shares, compared to its average volume of 408,177. The company has a market capitalization of $800.30 million, a price-to-earnings ratio of -10.82 and a beta of 1.74. The stock's 50 day moving average price is $24.70 and its 200 day moving average price is $26.60. Dianthus Therapeutics, Inc. has a 52 week low of $10.65 and a 52 week high of $33.77.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on DNTH shares. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating on the stock. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. Oppenheimer increased their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $46.43.
View Our Latest Research Report on Dianthus Therapeutics
About Dianthus Therapeutics
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
